Previous Close | 21.40 |
Open | 21.40 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 21.40 - 21.40 |
52 Week Range | 20.48 - 30.00 |
Volume | |
Avg. Volume | 0 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Jul 22, 2024 - Jul 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.